U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H28N4O4.3H2O
Molecular Weight 382.4531
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PERAMIVIR

SMILES

O.O.O.[H][C@@]1([C@@H](NC(C)=O)C(CC)CC)[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O

InChI

InChIKey=RFUCJKFZFXNIGB-ZBBHRWOZSA-N
InChI=1S/C15H28N4O4.3H2O/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23;;;/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19);3*1H2/t9-,10+,11+,12-,13+;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H28N4O4
Molecular Weight 328.4072
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fdedaec-9e53-4a37-a4e4-a301c8a251b8; http://www.rxlist.com/script/main/art.asp?articlekey=185939

Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor. Rapivab (peramivir injection) is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days. Efficacy of Rapivab is based on clinical trials in which the predominant influenza virus type was influenza A and a limited number of subjects infected with influenza B virus were enrolled. Since influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness. Other factors such as changes in viral virulence might also diminish clinical benefit of antiviral drug. Efficacy could not be established in patients with serious influenza requiring hospitalization.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: UNIPROT: O91745 (Neuraminidase)
0.08 nM [IC50]
0.22 nM [EC50]
0.045 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RAPIVAB

Approved Use

RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days.

Launch Date

1.4189472E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
46800 ng/mL
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERAMIVIR ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
102700 ng × h/mL
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERAMIVIR ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERAMIVIR ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PERAMIVIR ANHYDROUS serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Other AEs: Leukopenia, Neutropenia...
Other AEs:
Leukopenia (42.9%)
Neutropenia (14.3%)
Hyperglycemia (42.9%)
Hypertension (28.6%)
AST increased (14.3%)
ALT increased (14.3%)
Diarrhea (14.3%)
Sources: Page: 500
400 mg 2 times / day multiple, intravenous
Highest studied dose
Dose: 400 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
400 mg 2 times / day multiple, intravenous
Highest studied dose
Dose: 400 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 2 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M+F
Sources:
600 mg 1 times / day multiple, intramuscular
Highest studied dose
Dose: 600 mg, 1 times / day
Route: intramuscular
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 60
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources: Page: 60
800 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 800 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M
Sources:
800 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 800 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: M+F
Sources:
300 mg 1 times / day multiple, intravenous
Minumum effective dose
Dose: 300 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 363
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 363
Sources: Page: 98
Disc. AE: Lymphadenopathy, Gingival pain...
AEs leading to
discontinuation/dose reduction:
Lymphadenopathy (<1%)
Gingival pain (<1%)
Salivary gland pain (<1%)
Rash (<1%)
Sources: Page: 98
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 654
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 654
Sources: Page: 4
Other AEs: Alanine aminotransferase, Creatine phosphokinase...
Other AEs:
Alanine aminotransferase (grade 2-4, 3%)
Creatine phosphokinase (grade 2-4, 4%)
Neutrophils (grade 2-4, 8%)
Sources: Page: 4
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 660
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 660
Sources: Page: 4
Other AEs: Serum glucose...
Other AEs:
Serum glucose (grade 2-4, 5%)
Sources: Page: 4
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Disc. AE: Abdominal pain upper, Arthralgia...
AEs leading to
discontinuation/dose reduction:
Abdominal pain upper (<1%)
Arthralgia (<1%)
Drug eruption (<1%)
Eczema (<1%)
Rash (<1%)
Sources: Page: 98
AEs

AEs

AESignificanceDosePopulation
ALT increased 14.3%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
AST increased 14.3%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Diarrhea 14.3%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Neutropenia 14.3%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Hypertension 28.6%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Hyperglycemia 42.9%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Leukopenia 42.9%
11.4 mg/kg 1 times / day steady, intravenous (median)
Dose: 11.4 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 11.4 mg/kg, 1 times / day
Sources: Page: 500
unhealthy, 2.4-9.8 years
n = 7
Health Status: unhealthy
Condition: H1N1
Age Group: 2.4-9.8 years
Sex: M+F
Population Size: 7
Sources: Page: 500
Gingival pain <1%
Disc. AE
300 mg 1 times / day multiple, intravenous
Minumum effective dose
Dose: 300 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 363
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 363
Sources: Page: 98
Lymphadenopathy <1%
Disc. AE
300 mg 1 times / day multiple, intravenous
Minumum effective dose
Dose: 300 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 363
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 363
Sources: Page: 98
Rash <1%
Disc. AE
300 mg 1 times / day multiple, intravenous
Minumum effective dose
Dose: 300 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 363
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 363
Sources: Page: 98
Salivary gland pain <1%
Disc. AE
300 mg 1 times / day multiple, intravenous
Minumum effective dose
Dose: 300 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 363
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 363
Sources: Page: 98
Alanine aminotransferase grade 2-4, 3%
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 654
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 654
Sources: Page: 4
Creatine phosphokinase grade 2-4, 4%
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 654
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 654
Sources: Page: 4
Neutrophils grade 2-4, 8%
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 654
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 654
Sources: Page: 4
Serum glucose grade 2-4, 5%
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 4
unhealthy, adult
n = 660
Health Status: unhealthy
Condition: H1N1
Age Group: adult
Sex: unknown
Population Size: 660
Sources: Page: 4
Abdominal pain upper <1%
Disc. AE
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Arthralgia <1%
Disc. AE
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Drug eruption <1%
Disc. AE
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Eczema <1%
Disc. AE
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Rash <1%
Disc. AE
600 mg 1 times / day multiple, intravenous
Recommended
Dose: 600 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: 98
unhealthy, adult
n = 365
Health Status: unhealthy
Condition: acute uncomplicated influenza
Age Group: adult
Sex: unknown
Population Size: 365
Sources: Page: 98
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.
2001 Dec
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
2001 Dec 6
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
2001 Oct
Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201.
2001 Sep
Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.
2002 Jun
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
2002 May 23
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds.
2002 Oct
Patents

Sample Use Guides

The recommended dose of RAPIVAB in adult patients 18 years of age or older with acute uncomplicated influenza is a single 600 mg dose, administered via intravenous infusion for 15 to 30 minutes. The dose should be reduced for patients with baseline creatinine clearance below 50 mL/min to 200 mg dose (at 30-49 mL/min creatinine clearance), and 100 mg dose (at 10-29 mL/min creatinine clearance).
Route of Administration: Intravenous
The concentrations of peramivir required for inhibition of influenza virus in cell culture varied with the virus strain tested. The effect of antiviral compounds on the replication of influenza viruses in MDCK cells was determined by flow cytometric analysis of virus-infected cells. The mean 50% effective concentrations (EC50 values) of peramivir were in the range of 0.045-0.071 nM), 0.065-0.07 nM and 0.215-33.58 nM for influenza A/H1N1 virus, A/H3N2 virus, and B virus strains, respectively.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:00:17 UTC 2023
Edited
by admin
on Wed Jul 05 23:00:17 UTC 2023
Record UNII
QW7Y7ZR15U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PERAMIVIR
DASH   MART.   USAN   VANDF   WHO-DD  
USAN  
Official Name English
Peramivir [WHO-DD]
Common Name English
PERAMIVIR [MART.]
Common Name English
RAPIVAB
Brand Name English
BCX-1812
Code English
PERAMIVIR [USAN]
Common Name English
PERAMIVIR TRIHYDRATE [MI]
Common Name English
RAPIACTA
Brand Name English
Peramivir trihydrate [WHO-DD]
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 3-((1S)-1-(ACETYLAMINO)-2-ETHYLBUTYL)-4-((AMINOIMINOMETHYL)AMINO)-2-HYDROXY-, (1S,2S,3R,4R)-
Common Name English
PERAMIVIR TRIHYDRATE
MI  
Common Name English
(1S,2S,3R,4R)-3-((1S)-1-ACETYLAMINO-2-ETHYLBUTYL)-4-((AMINOIMINOMETHYL)AMINO)-2-HYDROXYCYCLOPENTANECARBOXYLIC ACID, TRIHYDRATE
Common Name English
PERAMIVIR HYDRATE
JAN  
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 3-((1S)-1-(ACETYLAMINO)-2-ETHYLBUTYL)-4-((AMINOIMINOMETHYL)AMINO)-2-HYDROXY-, HYDRATE (1:3), (1S,2S,3R,4R)-
Common Name English
(1S,2S,3R,4R)-3-((1S)-1-ACETAMIDO-2-ETHYLBUTYL)-4-((AMINO(IMINO)METHYL)AMINO)-2-HYDROXYCYCLOPENTANECARBOXYLIC ACID TRIHYDRATE
Systematic Name English
PERAMIVIR [ORANGE BOOK]
Common Name English
PERAMIVIR [VANDF]
Common Name English
PERAMIVIR HYDRATE [JAN]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AH03
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
NCI_THESAURUS C281
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
NDF-RT N0000175524
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
Code System Code Type Description
FDA UNII
QW7Y7ZR15U
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
RXCUI
619693
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY RxNorm
DAILYMED
QW7Y7ZR15U
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
CAS
1041434-82-5
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
LACTMED
Peramivir
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
PUBCHEM
11954371
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
EPA CompTox
DTXSID60146317
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
CHEBI
85196
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
ChEMBL
CHEMBL139367
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
USAN
WW-64
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
DRUG BANK
DB06614
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
DRUG CENTRAL
4823
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
MESH
C414210
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
CHEBI
85202
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
JAPANESE REVIEW
RAPIACTA
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY APPROVED JANUARY 2010
NCI_THESAURUS
C81611
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
SMS_ID
100000124542
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY
MERCK INDEX
M8534
Created by admin on Wed Jul 05 23:00:17 UTC 2023 , Edited by admin on Wed Jul 05 23:00:17 UTC 2023
PRIMARY Merck Index
Related Record Type Details
TARGET ORGANISM->INHIBITOR
ANHYDROUS->SOLVATE
TARGET ORGANISM->INHIBITOR
PARENT -> SALT/SOLVATE
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC